1. 444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx). (September 2015) Authors: Scher, H.I.; Kelvin, J.; Lu, D.; Louw, J.; Packer, D.; Bambury, R.; Rathkopf, D.; Schreiber, N.; Brennan, R.; Prigozhina, N.; Brown, D.; Jendrisak, A.; Dugan, L.; Landers, M.; Lee, F.; Fleisher, M.; Marrinucci, D.; Dittamore, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗